Prophylaxis against covid-19: living systematic review and network meta-analysis.
Journal
BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488
Informations de publication
Date de publication:
26 04 2021
26 04 2021
Historique:
entrez:
27
4
2021
pubmed:
28
4
2021
medline:
4
5
2021
Statut:
epublish
Résumé
This is the second version (first update) of the living systematic review, replacing the previous version (available as a data supplement). When citing this paper please consider adding the version number and date of access for clarity. To determine and compare the effects of drug prophylaxis on severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (covid-19). Living systematic review and network meta-analysis (NMA). World Health Organization covid-19 database, a comprehensive multilingual source of global covid-19 literature to 4 March 2022. Randomised trials in which people at risk of covid-19 were allocated to prophylaxis or no prophylaxis (standard care or placebo). Pairs of reviewers independently screened potentially eligible articles. After duplicate data abstraction, we conducted random-effects bayesian network meta-analysis. We assessed risk of bias of the included studies using a modification of the Cochrane risk of bias 2.0 tool and assessed the certainty of the evidence using the grading of recommendations assessment, development and evaluation (GRADE) approach. The second iteration of this living NMA includes 32 randomised trials which enrolled 25 147 participants and addressed 21 different prophylactic drugs; adding 21 trials (66%), 18 162 participants (75%) and 16 (76%) prophylactic drugs. Of the 16 prophylactic drugs analysed, none provided convincing evidence of a reduction in the risk of laboratory confirmed SARS-CoV-2 infection. For admission to hospital and mortality outcomes, no prophylactic drug proved different than standard care or placebo. Hydroxychloroquine and vitamin C combined with zinc probably increase the risk of adverse effects leading to drug discontinuation—risk difference for hydroxychloroquine (RD) 6 more per 1000 (95% credible interval (CrI) 2 more to 10 more); for vitamin C combined with zinc, RD 69 more per 1000 (47 more to 90 more), moderate certainty evidence. Much of the evidence remains very low certainty and we therefore anticipate future studies evaluating drugs for prophylaxis may change the results for SARS-CoV-2 infection, admission to hospital and mortality outcomes. Both hydroxychloroquine and vitamin C combined with zinc probably increase adverse effects. This review was not registered. The protocol established a priori is included as a supplement. This study was supported by the Canadian Institutes of Health Research (grant CIHR-IRSC:0579001321).
Identifiants
pubmed: 33903131
doi: 10.1136/bmj.n949
pmc: PMC8073806
doi:
Substances chimiques
Anti-Infective Agents
0
Hydroxychloroquine
4QWG6N8QKH
Ivermectin
70288-86-7
Carrageenan
9000-07-1
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
n949Commentaires et corrections
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: BS reports receiving funding from PIPRA AG (www.pipra.ch) to conduct a systematic review and individual patient data meta-analysis on predictors of postoperative delirium in elderly people in 2020-21; funding from Mitacs Canada, Accelerate internship in partnership with Nestlé Canada to support his graduate student stipend from 2016 to 2018. Mitacs is a national, not-for-profit organisation that has designed and delivered research and training programmes in Canada, working with universities, companies, and both federal and provincial governments; and funding from the International Life Sciences Institute (ILSI)-North America to support his graduate work for his 2015 academic year. In 2016-17, BS worked part-time for the Cornerstone Research Group (CRG), a contract research organisation. The ILSI funding and being employed by CRG are outside the required three year period requested on the ICJME form. ML reports personal fees and non-financial support from Sanofi, grants and personal fees from Seqirus, and personal fees from Pfizer and Medicago outside the submitted work; and is co-investigator on an Anti-Coronavirus Therapies (ACT) randomised trial of covid-19 treatment. LG reports grants from the Ministry of Science and Technology of China, outside the submitted work. All other authors report no financial relationships with any organisations that might have an interest in the submitted work in the previous three years and no other relationships or activities that could appear to have influenced the submitted work.
Références
Int J Infect Dis. 2022 Mar;116:167-173
pubmed: 34954095
BMJ. 2020 Sep 4;370:m3379
pubmed: 32887691
J Pharm Pharm Sci. 2020;23:462-469
pubmed: 33227231
Open Forum Infect Dis. 2020 Oct 19;7(11):ofaa500
pubmed: 33204764
Nutrients. 2022 Jan 05;14(1):
pubmed: 35011103
BMJ Open. 2022 Jun 1;12(6):e059540
pubmed: 35649613
Biomed Rep. 2022 Feb;16(2):11
pubmed: 34987795
Stat Med. 2015 Mar 15;34(6):984-98
pubmed: 25475839
Trials. 2021 Nov 15;22(1):808
pubmed: 34781981
Infect Agent Cancer. 2023 Feb 12;18(1):9
pubmed: 36782325
Nutrients. 2022 Jan 24;14(3):
pubmed: 35276863
Front Immunol. 2022 Jun 01;13:899617
pubmed: 35720389
J Am Coll Cardiol. 2020 Jul 21;76(3):268-276
pubmed: 32470515
Int J Infect Dis. 2022 Sep;122:553-558
pubmed: 35724828
Res Synth Methods. 2018 Dec;9(4):602-614
pubmed: 29314757
J Clin Med. 2022 Feb 21;11(4):
pubmed: 35207411
PLoS One. 2021 Aug 19;16(8):e0256401
pubmed: 34411199
BMJ. 2016 Sep 28;354:i5191
pubmed: 27680768
BMJ. 2022 Sep 7;378:e071230
pubmed: 36215226
Front Bioeng Biotechnol. 2021 Jun 24;9:646184
pubmed: 34249878
PLoS One. 2021 Jan 6;16(1):e0244778
pubmed: 33406138
Int J Gen Med. 2021 Oct 01;14:6277-6286
pubmed: 34629893
N Engl J Med. 2020 Aug 6;383(6):517-525
pubmed: 32492293
Cureus. 2021 Dec 21;13(12):e20572
pubmed: 35103151
BMJ. 2020 Nov 11;371:m3900
pubmed: 33177059
Am J Ther. 2021 Aug 16;28(5):e601-e604
pubmed: 34491960
PLoS One. 2022 Feb 9;17(2):e0261980
pubmed: 35139097
Ann Intern Med. 2015 Jun 2;162(11):777-84
pubmed: 26030634
JAMA Netw Open. 2021 Feb 1;4(2):e210369
pubmed: 33576820
EClinicalMedicine. 2021 Dec;42:101188
pubmed: 34778734
Dan Med Bull. 1990 Jun;37(3):279-81
pubmed: 2192839
Curr HIV/AIDS Rep. 2015 Mar;12(1):127-38
pubmed: 25600106
BMJ. 2021 Mar 1;372:n526
pubmed: 33649077
Interdiscip Perspect Infect Dis. 2022 Jan 29;2022:4693121
pubmed: 35103059
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
BMJ. 2020 Jul 30;370:m2980
pubmed: 32732190
Clin Infect Dis. 2023 Feb 8;76(3):e477-e486
pubmed: 35579509
Arch Med Res. 2022 Jun;53(4):423-430
pubmed: 35487792
J Clin Epidemiol. 2017 Nov;91:23-30
pubmed: 28912002
Eur Geriatr Med. 2022 Dec;13(6):1343-1355
pubmed: 36385690
Int J Infect Dis. 2021 May;106:314-322
pubmed: 33864917
BMJ. 2014 Sep 24;349:g5630
pubmed: 25252733
Ann Intern Med. 2021 Mar;174(3):344-352
pubmed: 33284679
J Clin Virol. 2022 Oct;155:105248
pubmed: 35952426
Front Nutr. 2022 Aug 03;9:962566
pubmed: 35990320
Clin Infect Dis. 2021 Jun 1;72(11):e835-e843
pubmed: 33068425
BMJ. 2021 Sep 23;374:n2231
pubmed: 34556486
JAMA Intern Med. 2021 Feb 1;181(2):195-202
pubmed: 33001138
N Engl J Med. 2021 Sep 23;385(13):1184-1195
pubmed: 34347950
N Engl J Med. 2021 Feb 4;384(5):417-427
pubmed: 33289973
Res Synth Methods. 2016 Mar;7(1):80-93
pubmed: 26461181
CMAJ. 2020 Aug 10;192(32):E901-E906
pubmed: 32778601
Nutrients. 2022 Dec 30;15(1):
pubmed: 36615837
N Engl J Med. 2022 Jun 9;386(23):2188-2200
pubmed: 35443106
BMC Med. 2016 Mar 29;14:59
pubmed: 27025849
J Antimicrob Chemother. 2022 Sep 30;77(10):2706-2712
pubmed: 35953881
Clin Microbiol Infect. 2023 Jan;29(1):85-93
pubmed: 35940567
J Clin Epidemiol. 2018 Jan;93:36-44
pubmed: 29051107
Int J Infect Dis. 2023 Apr;129:40-48
pubmed: 36682681
PLoS One. 2013 Oct 03;8(10):e76654
pubmed: 24098547
J Clin Epidemiol. 2011 Apr;64(4):407-15
pubmed: 21247734
JAMA. 2021 Jul 6;326(1):46-55
pubmed: 34081073